Sun Pharma Showcases Major Research Advancements at 2026 AAD Annual Meeting

Sun Pharmaceutical Industries Limited has made a significant impact at the 2026 American Academy of Dermatology (AAD) Annual Meeting, held from March 27 to March 31 in Denver, Colorado. The company presented a total of 14 abstracts that reinforce its leadership in the dermatology and immunology sectors. The focus of these presentations is on enhancing the treatment options for patients suffering from conditions like psoriasis, alopecia areata, and acne.

Dr. Ahmad Naim, Senior Vice President and North American Chief Medical Officer at Sun Pharma, emphasized the importance of this research. According to Dr. Naim, “The data we are presenting at AAD underline our dedication to advancing the fields of dermatology and immunology through significant scientific insights—focusing not just on clinical effectiveness and safety but also on real-world applications and outcomes for patients.”

Advancements in Treatment Options

Among the highlights of the presentations, key studies included:

ILUMYA® (tildrakizumab-asmn)

A Phase 3b study evaluating ILUMYA showcased its sustained efficacy and safety in patients with moderate-to-severe psoriasis that affects the nails, demonstrating effective treatment over a period of 52 weeks. Noteworthy results showed that ILUMYA is effective not only for skin management but also for overall disease management across diverse patient populations in several countries, including the U.S., Europe, Australia, and Japan.

LEQSELVI™ (deuruxolitinib)

In studies pertaining to severe alopecia areata, pooled data from pivotal trials revealed significant scalp hair regrowth as early as Week 8, with ongoing improvements noted throughout the treatment period. A landmark survey highlighted discrepancies in patient and clinician perspectives on the disease, stressing the need for improved communication for more effective care delivery.

WINLEVI® (clascoterone cream 1%)

In acne treatment, results from an open-label study indicated that WINLEVI significantly reduced facial sebum production and acne severity over a 52-week duration. Initial findings from combination therapy trials further suggested that WINLEVI might enhance multimodal treatment approaches, indicating broader clinical applicability.

Engaging with Healthcare Professionals

During the conference, Sun Pharma engaged healthcare professionals through interactive booth experiences designed to bring the science supporting its dermatology and immunology portfolio to life. Attendees had opportunities to explore the implications of innovative therapies in improving patient quality of life.

The abstracts presented at the conference outline various aspects of Sun Pharma's commitment to addressing chronic skin conditions and underscore its ongoing investment in research and development. The company continues to strive for advancements that translate into meaningful clinical outcomes for patients dealing with these diseases.

For those interested in exploring the presentation abstracts further, the e-Posters from the 2026 AAD Annual Meeting are available online, showcasing a comprehensive overview of Sun Pharma's research efforts in the realm of dermatology and immunology, signifying the company's strong standing in the industry.